Flow Traders Us Holding In Credit Suisse Ag/Nassau (ZIV) Was Boosted; Blb&B Advisors Has Boosted Position in Astrazeneca Plc (AZN) as Stock Rose

April 14, 2018 - By Clifton Ray

AstraZeneca PLC (NYSE:AZN) Logo

Blb&B Advisors Llc increased its stake in Astrazeneca Plc (AZN) by 133.79% based on its latest 2017Q4 regulatory filing with the SEC. Blb&B Advisors Llc bought 31,388 shares as the company’s stock rose 3.15% while stock markets declined. The institutional investor held 54,849 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.90M, up from 23,461 at the end of the previous reported quarter. Blb&B Advisors Llc who had been investing in Astrazeneca Plc for a number of months, seems to be bullish on the $88.62B market cap company. The stock decreased 0.11% or $0.04 during the last trading session, reaching $36.32. About 3.16 million shares traded. AstraZeneca PLC (NYSE:AZN) has risen 9.03% since April 14, 2017 and is uptrending. It has underperformed by 2.52% the S&P500.

Flow Traders Us Llc increased its stake in Credit Suisse Ag/Nassau (ZIV) by 489.05% based on its latest 2017Q4 regulatory filing with the SEC. Flow Traders Us Llc bought 14,290 shares as the company’s stock declined 28.18% with the market. The institutional investor held 17,212 shares of the investment bankers and brokers and service company at the end of 2017Q4, valued at $1.53 million, up from 2,922 at the end of the previous reported quarter. Flow Traders Us Llc who had been investing in Credit Suisse Ag/Nassau for a number of months, seems to be bullish on the $113.44M market cap company. The stock increased 1.79% or $1.13 during the last trading session, reaching $64.36. About 80,084 shares traded. VelocityShares Daily Inverse VIX MT ETN (NASDAQ:ZIV) has risen 6.93% since April 14, 2017 and is uptrending. It has underperformed by 4.62% the S&P500.

Flow Traders Us Llc, which manages about $1.10B US Long portfolio, decreased its stake in Xtrackers Msci Eurozone Hedged by 58,453 shares to 27,776 shares, valued at $843,000 in 2017Q4, according to the filing. It also reduced its holding in Ishares Emerging Markets High by 12,744 shares in the quarter, leaving it with 52,918 shares, and cut its stake in Ishares Msci United Kingdom Et.

Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 17 have Buy rating, 0 Sell and 9 Hold. Therefore 65% are positive. AstraZeneca plc (ADR) had 45 analyst reports since July 31, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of AZN in report on Thursday, January 18 with “Hold” rating. BMO Capital Markets initiated the stock with “Buy” rating in Wednesday, September 6 report. The stock of AstraZeneca PLC (NYSE:AZN) earned “Outperform” rating by Bernstein on Friday, September 22. The company was downgraded on Thursday, September 14 by Liberum Capital. The stock of AstraZeneca PLC (NYSE:AZN) earned “Hold” rating by HBSC on Monday, February 8. Credit Suisse upgraded AstraZeneca PLC (NYSE:AZN) on Monday, October 16 to “Buy” rating. The firm earned “Equal-Weight” rating on Tuesday, January 19 by Barclays Capital. As per Wednesday, August 9, the company rating was maintained by Piper Jaffray. The firm has “Neutral” rating given on Friday, May 12 by Credit Suisse. As per Tuesday, March 15, the company rating was downgraded by Jefferies.

Blb&B Advisors Llc, which manages about $669.27 million and $699.73M US Long portfolio, decreased its stake in Glaxosmithkline Plc (NYSE:GSK) by 9,441 shares to 53,585 shares, valued at $1.90M in 2017Q4, according to the filing. It also reduced its holding in Qualcomm Inc (NASDAQ:QCOM) by 8,362 shares in the quarter, leaving it with 64,915 shares, and cut its stake in Vodafone Group Plc New (NASDAQ:VOD).

AstraZeneca PLC (NYSE:AZN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>